A Phase 1b/2, Open-label, Randomized Study of MEDI-573 in Combination With Sorafenib Verses Sorafenib Alone in Adult Subjects With Unresectable or Metastatic Hepatocellular Carcinoma.
Phase of Trial: Phase I/II
Latest Information Update: 26 Nov 2013
At a glance
- Drugs Dusigitumab (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions
- 01 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Oct 2013 Planned end date changed from 1 May 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 14 May 2013 Planned number of patients changed from 9 to 6 as reported by ClinicalTrials.gov record.